1192 related articles for article (PubMed ID: 16617388)
41. SUV correction for injection errors in FDG-PET examination.
Miyashita K; Takahashi N; Oka T; Asakawa S; Lee J; Shizukuishi K; Inoue T
Ann Nucl Med; 2007 Dec; 21(10):607-13. PubMed ID: 18092139
[TBL] [Abstract][Full Text] [Related]
42. Fluoro-deoxy-glucose positron emission tomography for evaluation of indeterminate lung nodules: assigning a probability of malignancy may be preferable to binary readings.
Kim SC; Machac J; Krynyckyi BR; Knesaurek K; Krellenstein D; Schultz B; Gribetz A; DePalo L; Teirstein A; Kim CK
Ann Nucl Med; 2008 Apr; 22(3):165-70. PubMed ID: 18498030
[TBL] [Abstract][Full Text] [Related]
43. Methodologic Considerations for Quantitative 18F-FDG PET/CT Studies of Hepatic Glucose Metabolism in Healthy Subjects.
Trägårdh M; Møller N; Sørensen M
J Nucl Med; 2015 Sep; 56(9):1366-71. PubMed ID: 26159590
[TBL] [Abstract][Full Text] [Related]
44. Comparative assessment of methods for estimating tumor volume and standardized uptake value in (18)F-FDG PET.
Tylski P; Stute S; Grotus N; Doyeux K; Hapdey S; Gardin I; Vanderlinden B; Buvat I
J Nucl Med; 2010 Feb; 51(2):268-76. PubMed ID: 20080896
[TBL] [Abstract][Full Text] [Related]
45. [The application of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer].
Xu HF; Liu Y; Zhang JH; Zhou RS; Zhou FH; Yuan MH
Zhonghua Jie He He Hu Xi Za Zhi; 2005 Feb; 28(2):108-11. PubMed ID: 15854393
[TBL] [Abstract][Full Text] [Related]
46. Optimizing positron emission tomography image acquisition protocols in integrated positron emission tomography/magnetic resonance imaging.
Hartung-Knemeyer V; Beiderwellen KJ; Buchbender C; Kuehl H; Lauenstein TC; Bockisch A; Poeppel TD
Invest Radiol; 2013 May; 48(5):290-4. PubMed ID: 23399811
[TBL] [Abstract][Full Text] [Related]
47. Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods?
Pöpperl G; Kreth FW; Herms J; Koch W; Mehrkens JH; Gildehaus FJ; Kretzschmar HA; Tonn JC; Tatsch K
J Nucl Med; 2006 Mar; 47(3):393-403. PubMed ID: 16513607
[TBL] [Abstract][Full Text] [Related]
48. FDG uptake heterogeneity evaluated by fractal analysis improves the differential diagnosis of pulmonary nodules.
Miwa K; Inubushi M; Wagatsuma K; Nagao M; Murata T; Koyama M; Koizumi M; Sasaki M
Eur J Radiol; 2014 Apr; 83(4):715-9. PubMed ID: 24418285
[TBL] [Abstract][Full Text] [Related]
49. Regional nodal staging with 18F-FDG PET-CT in non-small cell lung cancer: Additional diagnostic value of CT attenuation and dual-time-point imaging.
Li M; Wu N; Liu Y; Zheng R; Liang Y; Zhang W; Zhao P
Eur J Radiol; 2012 Aug; 81(8):1886-90. PubMed ID: 21511421
[TBL] [Abstract][Full Text] [Related]
50. FDG-PET and CT characterization of adrenal lesions in cancer patients.
Jana S; Zhang T; Milstein DM; Isasi CR; Blaufox MD
Eur J Nucl Med Mol Imaging; 2006 Jan; 33(1):29-35. PubMed ID: 16193311
[TBL] [Abstract][Full Text] [Related]
51. Diagnostic accuracy of FDG PET imaging for the detection of recurrent or metastatic gynecologic cancer.
Khan N; Oriuchi N; Yoshizaki A; Kanuma T; Higuchi T; Endo K
Ann Nucl Med; 2005 Apr; 19(2):137-45. PubMed ID: 15909494
[TBL] [Abstract][Full Text] [Related]
52. Treatment response evaluation with
Sachpekidis C; Hillengass J; Goldschmidt H; Wagner B; Haberkorn U; Kopka K; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):50-62. PubMed ID: 27573638
[TBL] [Abstract][Full Text] [Related]
53. Evaluation of delayed 18F-FDG PET in differential diagnosis for malignant soft-tissue tumors.
Hamada K; Tomita Y; Ueda T; Enomoto K; Kakunaga S; Myoui A; Higuchi I; Yoshikawa H; Hatazawa J
Ann Nucl Med; 2006 Dec; 20(10):671-5. PubMed ID: 17385305
[TBL] [Abstract][Full Text] [Related]
54. Influence of Statistical Fluctuation on Reproducibility and Accuracy of SUVmax and SUVpeak: A Phantom Study.
Akamatsu G; Ikari Y; Nishida H; Nishio T; Ohnishi A; Maebatake A; Sasaki M; Senda M
J Nucl Med Technol; 2015 Sep; 43(3):222-6. PubMed ID: 26271802
[TBL] [Abstract][Full Text] [Related]
55. Is liver SUV stable over time in ¹⁸F-FDG PET imaging?
Laffon E; Adhoute X; de Clermont H; Marthan R
J Nucl Med Technol; 2011 Dec; 39(4):258-63. PubMed ID: 21878481
[TBL] [Abstract][Full Text] [Related]
56. Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
Kahraman D; Scheffler M; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Ullrich RT; Holstein A; Dietlein M; Wolf J; Kobe C
J Nucl Med; 2011 Dec; 52(12):1871-7. PubMed ID: 22065872
[TBL] [Abstract][Full Text] [Related]
57. Evaluation of delayed additional FDG PET imaging in patients with pancreatic tumour.
Nishiyama Y; Yamamoto Y; Monden T; Sasakawa Y; Tsutsui K; Wakabayashi H; Ohkawa M
Nucl Med Commun; 2005 Oct; 26(10):895-901. PubMed ID: 16160649
[TBL] [Abstract][Full Text] [Related]
58. The value of dual time point (18)F-FDG PET imaging for the differentiation between malignant and benign lesions.
Lan XL; Zhang YX; Wu ZJ; Jia Q; Wei H; Gao ZR
Clin Radiol; 2008 Jul; 63(7):756-64. PubMed ID: 18555033
[TBL] [Abstract][Full Text] [Related]
59. Dual time point 2-[18F]fluoro-2'-deoxyglucose positron emission tomography in chronic bacterial osteomyelitis.
Sahlmann CO; Siefker U; Lehmann K; Meller J
Nucl Med Commun; 2004 Aug; 25(8):819-23. PubMed ID: 15266177
[TBL] [Abstract][Full Text] [Related]
60. Positron Emission Tomography: Current Role for Diagnosis and Therapy Monitoring in Oncology.
Strauss LG
Oncologist; 1997; 2(6):381-388. PubMed ID: 10388073
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
